uPAR-PET/CT Tracers for HNSCC Relapse Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable prognostic tools for identifying candidates for de-escalated treatment in head and neck squamous cell carcinoma (HNSCC), particularly for HPV-positive tumors, and existing biomarkers like 18F-FDG-PET provide inconsistent results.
Innovation Solution
Development of uPAR-PET tracers, such as 68Ga-NOTA-AE105, for PET/CT imaging to assess uPAR expression, which correlates with relapse-free survival (RFS) in HNSCC patients, allowing for risk stratification and de-escalated treatment selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If 18F-FDG-PET is used for prognostication in HNSCC patients, then metabolic activity can be assessed, but the results are inconsistent and lack reliability
Solution Approach 1:
The patent changes the biochemical parameter being measured from general glucose metabolism (18F-FDG) to specific uPAR receptor expression (68Ga-NOTA-AE105). This parameter change targets the specific molecular mechanism driving tumor invasion and metastasis, providing more consistent and reliable prognostic information for HNSCC patients.
Solution Approach 2:
The patent introduces uPAR as an intermediary biomarker that specifically mediates the relationship between tumor biology and clinical outcome. By using 68Ga-NOTA-AE105 to target uPAR, the system provides a more direct and reliable connection to tumor aggressiveness and relapse risk compared to the non-specific 18F-FDG metabolic imaging.
2Object-affected harmful factors
If de-escalated treatment regimens are applied to HPV-positive HNSCC patients, then treatment toxicity is reduced, but survival outcomes deteriorate due to lack of reliable risk stratification
Solution Approach 1:
The patent applies local quality by using 68Ga-NOTA-AE105 PET imaging to identify specific subgroups of patients with low uPAR expression who would benefit from de-escalated treatment. This allows treatment intensity to be locally optimized based on individual tumor biology rather than applying uniform de-escalation to all HPV-positive patients, maintaining survival outcomes while reducing toxicity in appropriate candidates.
Solution Approach 2:
The patent implements feedback by using uPAR-PET imaging results to guide treatment decisions. The imaging provides real-time biological feedback about tumor aggressiveness, allowing clinicians to adjust treatment intensity accordingly - reducing therapy for low-uPAR patients and maintaining aggressive therapy for high-uPAR patients, thus preserving survival outcomes while minimizing unnecessary toxicity.
3Measurement precision
If 68Ga-NOTA-AE105 is used for uPAR-PET imaging, then relapse-free survival prediction is improved, but the complexity of the imaging protocol increases
Solution Approach 1:
The patent leverages the universality of 68Ga labeling chemistry and PET imaging technology. The 68Ga radionuclide can be easily chelated to the NOTA-peptide conjugate using established protocols, and the imaging is performed on standard PET/CT scanners already available in clinical settings. This multi-functionality approach maintains high prognostic precision while minimizing protocol complexity by using universally available technologies.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to the a positron-emitting imaging agent for use in the prognosis of a head and neck cancer (HNSCC) in a subject by PET imaging of the cancer, wherein said imaging agent comprises a uPAR bindingpeptide coupled via the chelating agent NOTA or DOTA to the radionuclide 568Ga or 64Cu.